Fenofibrate and Propranolol in Burn Patients

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Burn

In brief

The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

Key facts

Study ID

NCT02452255

Run by

The University of Texas Medical Branch, Galveston

People needed

18

Starts

2015-11-01

Expected to finish

2019-07-12

Last updated by the study team

2019-11-29

Who can join

Age: any, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 0 through 80 years
• ≥ 20% Total Body Surface Area Burn injury

You may not qualify if…

• Pregnancy
• History or existence of pre-burn injury conditions
• Allergies to propranolol or fenofibrate
• Asthma requiring treatment
• Congestive heart failure (measured ejection fraction < 20%)
• Renal or hepatic disease
• Medical condition requiring glucocorticoid treatment
• History of AIDS, Aids Related Complex or HIV
• History of Cancer within 5 years
• Decision not to treat due to burn injury severity or futility as deemed by the clinical team

Where it is running

• Shriners Hospitals for Children — Galveston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.